Michael Yin

Dr. Michael Yin

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Science Translational Medicine
Verified
Journal Article
Open access
Lihong LiuLihong Liu
Lihong Liu
SISho Iketani
Sho Iketani
YGYicheng guo
Yicheng guo
EREswar R. Reddem
Eswar R. Reddem
RCRyan G. Casner
Ryan G. Casner
DHDavid Ho
David Ho
The devastation caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made clear the importance of pandemic preparedness. To address future zoonotic outbreaks due to related viruses in the sarbecovirus subgenus, we identified a human monoclonal antibody, 10-40, that neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo. Comparative studies with other receptor-binding domain (RBD)–directed antibodies showed 10-40 to have the greatest breadth against sarbecoviruses, suggesting that 10-40 is a promising agent for pandemic preparedness. Moreover, structural analyses on 10-40 and similar antibodies not only defined an epitope cluster in the inner face of the RBD that is well conserved among sarbecoviruses but also uncovered a distinct antibody class with a common CDRH3 motif. Our analyses also suggested that elicitation of this class of antibodies may not be overly difficult, an observation that bodes well for the development of a pan-sarbecovirus vaccine.

15 August 2016 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
MYMichael Yin
Michael Yin
SSStephanie Shiau
Stephanie Shiau
DRDavid Rimland
David Rimland
CGCynthia L. Gibert
Cynthia L. Gibert
RBRoger J. Bedimo
Roger J. Bedimo
JWJulie A. Cnm Womack
Julie A. Cnm Womack
Background: FRAX is a validated, computer-based clinical fracture risk calculator that estimates the 10-year risk of major osteoporotic (clinical spine, forearm, hip, or shoulder) fracture, and hip fracture alone. It is widely used for decision making in fracture prevention, but it may underestimate the risk in HIV-infected individuals. Some experts recommend considering HIV as a cause of secondary osteoporosis when calculating FRAX in HIV-infected individuals. Methods: From the Veterans Aging Cohort Study Virtual Cohort, we included 24,451 HIV-infected and uninfected men aged 50–70 years with complete data in the year 2000 to approximate all but 2 factors (ie, history of secondary osteoporosis and parental hip fracture) for modified-FRAX calculation without bone density and 10-year observational data for incident fragility fracture. The accuracy of the modified-FRAX calculation was compared by the observed/estimated (O/E) ratios of fracture by HIV status. Results: The accuracy of modified-FRAX was less for HIV-infected [O/E = 1.62, 95% confidence interval (CI) 1.45 to 1.81] than uninfected men (O/E = 1.29, 95% CI: 1.19 to 1.40), but improved when HIV was included as a cause of secondary osteoporosis (O/E = 1.20, 95% CI: 1.08 to 1.34). However, only 3%–6% of men with incident fractures were correctly identified by the modified-FRAX using accepted FRAX thresholds for pharmacologic therapy. Conclusions: Modified-FRAX underestimated the fracture rates more in older HIV-infected than in otherwise similar uninfected men. The accuracy improved when HIV was included as a cause of secondary osteoporosis, but it still performed poorly for case finding. Further studies are necessary to determine how to use FRAX or define an HIV-specific index to risk stratify for screening and treatment in older HIV-infected individuals.

1 November 2021 in Diabetes & Metabolism
Verified
Journal Article
Closed access
JSJ.S. Stevens
J.S. Stevens
MBM.M. Bogun
M.M. Bogun
DMD.J. McMahon
D.J. McMahon
JZJ. Zucker
J. Zucker
PKPaul Kurlansky
Paul Kurlansky
UPU.B. Pajvani
U.B. Pajvani

10 June 2016 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
JMJohn S Manavalan
John S Manavalan
SAStephen Arpadi
Stephen Arpadi
STShenthuraan Tharmarajah
Shenthuraan Tharmarajah
JSJayesh Shah
Jayesh Shah
CZChiyuan A Zhang
Chiyuan A Zhang
MYMichael Yin
Michael Yin
Chronic immune activation associated with human immunodeficiency virus (HIV) infection may have negative consequences on bone acquisition in individuals infected with HIV early in life. Bone mineral density (BMD) and microarchitecture were characterized in 38 HIV‐infected men on antiretroviral therapy (18 perinatally‐infected, 20 adolescence‐infected) and 20 uninfected men age 20 to 25 years by dual‐energy X‐ray absorptiometry (DXA), high‐resolution peripheral quantitative computed tomography (HRpQCT). Flow cytometry was utilized to measure CD4+/CD8+ activation (HLADR+CD38+) and senescence (CD28–CD57+) and to quantify circulating osteogenic precursor (COP) cells in peripheral blood mononuclear cells using antibodies to RUNX2 and osteocalcin (OCN). Telomere lengths were measured in sorted COP cells using qPCR. DXA‐derived areal BMD Z‐scores and HRpQCT‐derived volumetric BMD (vBMD) measures were lower in HIV‐infected than uninfected men. Proportion of activated and senescent CD4+ and CD8+ T cells were higher in HIV‐infected than uninfected men. The percentage of COP cells (mean ± SE) was lower in HIV‐infected than uninfected (0.19% ± 0.02% versus 0.43% ± 0.06%; p < 0.0001) men, and also lower in perinatally‐infected than adolescence‐infected men (0.15% ± 0.02% versus 0.22% ± 0.03%; p < 0.04). A higher proportion of COP cells correlated with higher bone stiffness, a measure of bone strength, whereas a higher proportion of activated CD4+ T cells correlated with lower BMD and stiffness and lower proportion of COP cells. T cell activation with HIV‐infection was associated with decreased numbers of osteogenic precursors as well as lower peak bone mass and bone strength. © 2016 American Society for Bone and Mineral Research.

1 May 2016 in Current Opinion in HIV and AIDS
Verified
Journal Article
Closed access
MYMichael Yin
Michael Yin
JFJulian Falutz
Julian Falutz
Purpose of review Skeletal fractures are more common in HIV, and impact the medical, functional and economic status of frequently vulnerable patients. Identifying asymptomatic patients with low bone mineral density (BMD)/osteoporosis requiring intervention can be expected to reduce fracture risk and complications. Clinical tools are available to determine fracture risk in the general population and are being evaluated in HIV patients. The FRAX® calculator, incorporating demographics and risk factors for osteoporosis, with or without BMD results, has been investigated most often in HIV patients. Recent findings The few published studies that have calculated the 10-year FRAX® risk for both major osteoporosis and hip fractures without BMD generally show limited precision in predicting the presence of osteoporosis severe enough to initiate treatment. It remains uncertain whether using HIV as a secondary risk factor and adding dual X-ray absorptiometry (DXA)-BMD information improves case-finding compared with using DXA results only. Not incorporating risks relevant to aging HIV patients such as antiretroviral exposure, hepatitis C virus coinfection and history of falls is other potential limitation. Summary Accurate screening tools using clinical risk factors alone to determine fracture risk in HIV are not yet available. Further research and validation studies are necessary.

11 October 2016 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
MYMichael Yin
Michael Yin
TBTodd T. Brown
Todd T. Brown